z-Movi

Blog posts

Cell Avidity uncovers critical binding mechanism impairing T-cell potency in the Tumor Microenvironment

A key mechanism deployed by the TME is the upregulation of immune checkpoint molecules. The BTLA-HVEM interaction between CAR-T cells and tumor cells has emerged as a critical factor in T-cell inhibition and exhaustion. This article covers the excellent work of researchers at UPenn that deleted BTLA in CAR-T cells.…

niels1 August 2024

Blog posts

Cell Avidity screening deployed by T cell pioneers to accelerate the identification of functional TCRs

The TCR field continues to rely on a protracted preclinical selection process, which utilizes conventional assays such as affinity and peptide titrations that correlate poorly with T-cell functionality. Optimal TCR selection necessitates thorough preclinical characterization, prompting Carr et al., to focus on comprehensive cell-cell binding assessment to enhance preclinical decision-making.

niels25 June 2024

Blog posts

Cell avidity-tuning ensures safe CAR-T therapy for solid tumors

Dive into our latest article where we shine the spotlight on the groundbreaking work carried out at the Dana-Farber Cancer Institute at Harvard Medical School where researchers utilized cell avidity-tuning to ensure the safety of their CAR-T therapy for targeting solid tumors.

niels5 June 2024

Press releases

Breakthrough Research Published in Nature Enabled by Dynamic Single-Molecule Analysis Reveals Crucial Structure-Function Insights into DNA Repair, Resulting in New Cancer Fighting Strategies

Amsterdam, the Netherlands – July 14th, 2023 – LUMICKS, a cutting-edge life science tools company and the leading supplier of dynamic single-molecule and cell avidity analysis instruments, today announced the publication of ground-breaking cancer research in Nature. The research, enabled by LUMICKS’ C-Trap® dynamic single-molecule analysis technology, reveals new crucial…

j.yeh19 July 2023

“Avidity Enhancement” As New Strategy for Improving CAR T Therapy for AML

Press releases

Cancer Cell Paper Identifies “Avidity Enhancement” As New Strategy for Improving CAR T Therapy for Acute Myeloid Leukemia

The study details a novel strategy for better cancer treatment with CAR T cells for AML. "Avidity Enhancement", increasing cell-cell binding from both the tumor and CAR T cell side, led to a more effective eradication of tumors in mouse models of AML.

j.yeh24 May 2022

Press releases

Nature Paper Identifies “Avidity Escape” as Solid Tumor Evasion Mechanism of CAR T Cell Cancer Therapies

In this study led by the team of Dr. Marcela Maus at Harvard Medical School, the LUMICKS z-Movi® Cell Avidity Analyzer showed that loss of interferon-γ receptor (IFNγR) signaling decreased cell binding avidity between CAR T cells and their target solid tumor cells.

j.yeh2 May 2022

Gosse Adema Professor, Radboud University Medical Centre Nijmegen

Press releases

New Study Highlights Cell Avidity’s Power to Provide Insights into the Robustness of T Cell Activation

New study by the team of Professor Gosse Adema demonstrates how cell avidity can be used to assess the effect of lead compounds on immune cells.

j.yeh22 March 2022

Press releases

Frontiers in Immunology Paper Discloses Promising New Insights into CAR-T Cell Efficacy for Cancer Therapies

Dr. Maher’s powerful research underscores the insights that our revolutionary technology can help researchers around the world discover, and help science better address core challenges in human health, particularly in designing potentially more effective immunotherapies to fight cancer.

j.yeh17 March 2022

Maria Themeli, Amsterdam AMC, T cell sensitivity and persistence, blood cancers, z-Movi, Cell Avidity analysis

Press releases

New study published in Translational Medicine highlights cell avidity’s power as a functional biomarker for improved CAR-T design in preventing tumor escape

Using cell avidity measurements and traditional immuno-assays, the researchers successfully demonstrated that co-expression of costimulatory receptors along with an FDA approved BCMA and CD19 CAR can improve both durability of potential treatments as well as persistence for common blood cancers.

j.yeh23 January 2022

Blog posts

LUMICKS z-Movi^® installed at Charité to measure TCR avidity in T cell therapy research

We are excited to announce the installation of a z-Movi® Cell Avidity Analyzer at Charité – Universitätsmedizin Berlin! The z-Movi will be used by the research team led by Dr. Matthias Leisegang, Juniorprofessor at the Institute of Immunology. This unique instrument measures the interaction strength between target tumor cells and effector…